RE: Antares pharma17 Feb 2019 09:23
CFP, if they aim to raise over $10mil it will disiminate the share and that level of dilution will no doubt see people jumping off the ship, which only snowballs any drop in share price
I can’t see how that can justify raising anymore that $5mil at this stage, which, if they run cash preservation I would like to think would last them to the end of 2019. At which point they could reassess and be hopefully further down the line with the FDA and have a share price higher
The target price of 115p on approval would no doubt be diluted to around 50-80p (worst case) which you then have to ask is the time/risk/reward worth it
Interesting times ahead